Literature DB >> 19131645

Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex.

Gongxiong Wu1, Weiguo Hu, Aliakbar Shahsafaei, Wenping Song, Martin Dobarro, Galina K Sukhova, Rod R Bronson, Guo-Ping Shi, Russell P Rother, Jose A Halperin, Xuebin Qin.   

Abstract

Complement is a central effector system within the immune system and is implicated in a range of inflammatory disorders. CD59 is a key regulator of complement membrane attack complex (MAC) assembly. The atherogenic role of terminal complement has long been suspected but is still unclear. Here, we demonstrate that among mice deficient in apolipoprotein (Apo)E, the additional loss of murine CD59 (mCd59ab(-/-)/ApoE(-/-)) accelerated advanced atherosclerosis featuring occlusive coronary atherosclerosis, vulnerable plaque, and premature death and that these effect could be attenuated by overexpression of human CD59 in the endothelium. Complement inhibition using a neutralizing anti-mouse C5 antibody attenuated atherosclerosis in mCd59ab(-/-)/ApoE(-/-) mice. Furthermore, MAC mediated endothelial damage and promoted foam cell formation. These combined results highlight the atherogenic role of MAC and the atheroprotective role of CD59 and suggest that inhibition of MAC formation may provide a therapeutic approach for the treatment of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19131645      PMCID: PMC4267695          DOI: 10.1161/CIRCRESAHA.108.191361

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  43 in total

1.  Local activation of the complement system in endoneurial microvessels of diabetic neuropathy.

Authors:  G B Rosoklija; A J Dwork; D S Younger; G Karlikaya; N Latov; A P Hays
Journal:  Acta Neuropathol       Date:  2000-01       Impact factor: 17.088

Review 2.  Complement and complement regulatory proteins as potential molecular targets for vascular diseases.

Authors:  Juan Acosta; Xuebin Qin; Jose Halperin
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

3.  ApoE(-/-) mice develop atherosclerosis in the absence of complement component C5.

Authors:  S Patel; E M Thelander; M Hernandez; J Montenegro; H Hassing; C Burton; S Mundt; A Hermanowski-Vosatka; S D Wright; Y S Chao; P A Detmers
Journal:  Biochem Biophys Res Commun       Date:  2001-08-10       Impact factor: 3.575

4.  Early complement activation and decreased levels of glycosylphosphatidylinositol-anchored complement inhibitors in human and experimental diabetic retinopathy.

Authors:  Jing Zhang; Chiara Gerhardinger; Mara Lorenzi
Journal:  Diabetes       Date:  2002-12       Impact factor: 9.461

5.  C5b-9-induced endothelial cell proliferation and migration are dependent on Akt inactivation of forkhead transcription factor FOXO1.

Authors:  Matthew Fosbrink; Florin Niculescu; Violeta Rus; Moon L Shin; Horea Rus
Journal:  J Biol Chem       Date:  2006-05-02       Impact factor: 5.157

6.  High-level endothelial expression of human CD59 prolongs heart function in an ex vivo model of xenograft rejection.

Authors:  P J Cowan; C A Somerville; T A Shinkel; M Katerelos; A Aminian; M Romanella; M J Tange; M J Pearse; A J d'Apice
Journal:  Transplantation       Date:  1998-03-27       Impact factor: 4.939

7.  Generation and phenotyping of mCd59a and mCd59b double-knockout mice.

Authors:  Xuebin Qin; Weiguo Hu; Wenping Song; Luciano Grubissich; Xuemei Hu; Gongxiong Wu; Sean Ferris; Martin Dobarro; Jose A Halperin
Journal:  Am J Hematol       Date:  2009-02       Impact factor: 10.047

8.  Analysis of the promoters and 5'-UTR of mouse Cd59 genes, and of their functional activity in erythrocytes.

Authors:  X Qin; S Ferris; W Hu; F Guo; G Ziegeler; J A Halperin
Journal:  Genes Immun       Date:  2006-03-16       Impact factor: 2.676

9.  Macrophage-specific transgenic expression of cholesteryl ester hydrolase significantly reduces atherosclerosis and lesion necrosis in Ldlr mice.

Authors:  Bin Zhao; Jingmei Song; Woon N Chow; Richard W St Clair; Lawrence L Rudel; Shobha Ghosh
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

10.  IgG binding to cytoskeletal intermediate filaments activates the complement cascade.

Authors:  G K Hansson; E Lagerstedt; A Bengtsson; M Heideman
Journal:  Exp Cell Res       Date:  1987-06       Impact factor: 3.905

View more
  51 in total

1.  The alternative pathway is critical for pathogenic complement activation in endotoxin- and diet-induced atherosclerosis in low-density lipoprotein receptor-deficient mice.

Authors:  Talat H Malik; Andrea Cortini; Daniele Carassiti; Joseph J Boyle; Dorian O Haskard; Marina Botto
Journal:  Circulation       Date:  2010-10-25       Impact factor: 29.690

2.  Lack of complement inhibitors in the outer intracranial artery aneurysm wall associates with complement terminal pathway activation.

Authors:  Riikka Tulamo; Juhana Frösen; Anders Paetau; Sanna Seitsonen; Juha Hernesniemi; Mika Niemelä; Irma Järvelä; Seppo Meri
Journal:  Am J Pathol       Date:  2010-10-22       Impact factor: 4.307

Review 3.  Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets.

Authors:  Pauline L Martin; Peter J Bugelski
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 4.  Complementing the inflammasome.

Authors:  Martha Triantafilou; Timothy R Hughes; Bryan Paul Morgan; Kathy Triantafilou
Journal:  Immunology       Date:  2016-02       Impact factor: 7.397

5.  Targeted mouse complement inhibitor CR2-Crry protects against the development of atherosclerosis in mice.

Authors:  Fengming Liu; Lin Wu; Gongxiong Wu; Chun Wang; Lining Zhang; Stephen Tomlinson; Xuebin Qin
Journal:  Atherosclerosis       Date:  2014-03-15       Impact factor: 5.162

6.  The protective role of CD59 and pathogenic role of complement in hepatic ischemia and reperfusion injury.

Authors:  Jinyan Zhang; Weiguo Hu; Wei Xing; Tao You; Junming Xu; Xuebin Qin; Zhihai Peng
Journal:  Am J Pathol       Date:  2011-10-19       Impact factor: 4.307

7.  The intrinsic complement regulator decay-accelerating factor modulates the biological response to vascular injury.

Authors:  Masashi Sakuma; Toshifumi Morooka; Yunmei Wang; Can Shi; Kevin Croce; Huiyun Gao; Michael Strainic; M Edward Medof; Daniel I Simon
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-03-18       Impact factor: 8.311

8.  rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia.

Authors:  Xiaowen Ge; Lin Wu; Weiguo Hu; Stacey Fernandes; Chun Wang; Xu Li; Jennifer R Brown; Xuebin Qin
Journal:  Clin Cancer Res       Date:  2011-09-14       Impact factor: 12.531

9.  Membrane attack complex inhibitor CD59a protects against focal cerebral ischemia in mice.

Authors:  Denise Harhausen; Uldus Khojasteh; Philip F Stahel; B Paul Morgan; Wilfried Nietfeld; Ulrich Dirnagl; George Trendelenburg
Journal:  J Neuroinflammation       Date:  2010-03-04       Impact factor: 8.322

10.  The membrane attack complex of complement drives the progression of atherosclerosis in apolipoprotein E knockout mice.

Authors:  Ruth D Lewis; Christopher L Jackson; B Paul Morgan; Timothy R Hughes
Journal:  Mol Immunol       Date:  2009-12-02       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.